Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
about
Alloantibody Generation and Effector Function Following Sensitization to Human Leukocyte AntigenThe Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsTranslational research in kidney transplantation and the role of patient engagementThe perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejectionThe use of novel diagnostics to individualize immunosuppression following transplantationLate and chronic antibody-mediated rejection: main barrier to long term graft survivalMonocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.Antibody Subclass Repertoire and Graft Outcome Following Solid Organ TransplantationA Rationale for Age-Adapted Immunosuppression in Organ TransplantationThe Complement System and Antibody-Mediated Transplant RejectionThe Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies.Posttransplant allosensitization in low immunological risk kidney and kidney-pancreas graft recipientsAn adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodiesAntithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipientsAutologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipientsThe Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.HLA sensitisation: can it be prevented?Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodiesImpact of ABO Incompatibility on the Development of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients Presensitized to HLA.Utility of HLA Antibody Testing in Kidney Transplantation.Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.Many de novo donor-specific antibodies recognize β2 -microglobulin-free, but not intact HLA heterodimers.Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation.The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney TransplantationImpact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.Old game, new players: Linking classical theories to new trends in transplant immunology.Application of Operational Tolerance Signatures Are Limited by Variability and Type of Immunosuppression in Renal Transplant Recipients: A Cross-Sectional Study.Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft InjuryAssessing immunologic risk factors in transplantation.The specificity of acute and chronic microvascular alterations in renal allografts.Is it time to give up with calcineurin inhibitors in kidney transplantation?HLA antibody screening in kidney transplantation: current guidelines.Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms.Through a glass darkly: seeking clarity in preventing late kidney transplant failureThe increasing clinical importance of alloantibodies in kidney transplantation.Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation.Clinical relevance of HLA antibody monitoring after kidney transplantation.
P2860
Q26766411-B69E894E-070E-489E-8C49-D4318C89D96CQ26774993-A1D3AF7F-8F07-48BB-8889-0B468DC14B74Q26778752-D360DF75-C460-404C-8ABB-2796C60BF4A2Q26862195-D72EA9A2-E946-468F-A1A9-24D694011598Q26864686-388B4E6D-8892-48DC-9133-F81840E58857Q27006030-B1AC7296-71CC-4C53-8CDE-A5D3B21107F5Q27314948-3913FBD6-2F13-4C15-B467-F338CD5D6020Q28076193-0F0E04BF-20B4-41CE-A5E9-C3E8817E6CEDQ28080954-4A72804E-F382-4466-A042-B76813F055E5Q28087773-C42A8D3F-9A3A-4603-9203-A9C30D5E9D26Q30397251-2B71E052-1034-4FD3-AC26-32164C1D56E6Q33563056-91CAA0A7-B72B-4D85-A282-8D8880899FE6Q33865743-E954532C-6AB6-4AB6-848E-1A3CA2E7E755Q33930084-D13D41E9-CCFC-49C8-B2FB-BF5460D3C2C8Q34753440-D164528A-8CBB-4662-AAB2-7A5677F31BE8Q34995106-EB1DE04A-F14B-4ACD-846D-3BF0E33E9669Q35097898-D8D46843-E8B6-4D81-BE3C-13DC0B79E8DEQ35228551-BB0413D8-E1B8-4DBD-BD85-85290080CB7FQ35511754-B690F8B8-F3C8-4F21-80E4-E3A62E5A7CCAQ35790601-3EF7A04C-4265-4843-AC6D-BE8BEFA43967Q36246918-204990FA-6E67-4E51-B8F4-CABCE64A6E9DQ36509321-43B4A903-F26C-4AA5-ABC9-9B5959EA214EQ36514864-A39933E4-F487-4B63-BD5A-0B3E274E21BCQ36822826-6DB9E16B-91D1-4AD2-9618-D007123CFD46Q37352506-200C3A9D-A19A-45B3-B870-8440DF7C98C3Q37375622-C28E9540-18E1-4C20-BB39-2F10B9464CE0Q37481157-1C5E5A3A-F6FB-4944-8EE0-95DA9CF202C3Q37660263-8299F415-34AB-48F1-B166-C74D8741E947Q37662989-45CE223F-757B-4774-9B21-7F31CF4C42B7Q37715369-4CFF6338-6D76-4CCC-AE3F-11636533ECBDQ37720377-7A9E79A8-1129-4EEE-91F0-9654CD237D09Q38131035-3C278F0B-C0A6-4C81-8B65-F325B1C4AEECQ38151921-3F9E7810-BEED-437F-BE86-9C52D4585D64Q38156847-22CF4A10-1B3E-499C-A924-56419D826769Q38165753-F752CF35-0C23-4A8B-AC56-B8D0BF9C8D1CQ38169496-A663FA81-E843-4895-A998-20A392D5FEE3Q38237365-E0FF0624-6481-475A-B079-3516E387740FQ38258153-31392E57-03DB-40E0-A843-8E38FEA89C5AQ38262909-899268B2-F03B-4F83-82D2-B9596408D849Q38265563-9321F922-FB39-4E5D-969E-0ACFE363F350
P2860
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
@en
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
@nl
type
label
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
@en
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
@nl
prefLabel
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
@en
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
@nl
P2093
P1433
P1476
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
@en
P2093
Carl E Haisch
Karen Parker
Kimberly P Briley
Lorita M Rebellato
Matthew J Everly
Miyuki Ozawa
Paul Bolin
Paul G Catrou
Paul I Terasaki
Robert C Harland
P304
P356
10.1097/TP.0B013E31827D62E3
P577
2013-02-01T00:00:00Z